PTJ
ZVRA icon

Paul Tudor Jones’s Zevra Therapeutics ZVRA Stock Holding History

Paul Tudor Jones’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.3M Sell
90,800
-41,900
-32% -$466K ﹤0.01% 2227
2026
Q1 		$1.24M Buy
132,700
+18,100
+16% +$163K ﹤0.01% 2210
2025
Q4 		$1.03M Buy
114,600
+73,800
+181% +$698K ﹤0.01% 2257
2025
Q3 		$388K Buy
+40,800
New +$409K ﹤0.01% 2833

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Paul Tudor Jones's ZVRA Position: Q2 2026 in Review

Paul Tudor Jones reduced its Zevra Therapeutics (ZVRA) stake by 6.3% in Q2 2026, selling an estimated $312K and leaving 415,058 shares worth $5.95M. The position accounts for 0.01% of the portfolio, ranked #1160.

Paul Tudor Jones first reported a position in ZVRA in Q3 2025 and has held it in 4 quarters since. The position peaked at $6.2M in Q4 2025. 156 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

  • Paul Tudor Jones held 415,058 shares of Zevra Therapeutics worth $5.95M as of Q2 2026.
  • Paul Tudor Jones sold 28,051 Zevra Therapeutics shares in Q2 2026, an estimated $312K.
  • Zevra Therapeutics made up 0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #1160 holding.
  • Paul Tudor Jones first reported a position in Zevra Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Paul Tudor Jones's Zevra Therapeutics position peaked at $6.2M in Q4 2025.
  • 156 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.